Inactive Instrument

Roche Holding AG Stock Xetra

Equities

RHO5

CH0012032048

Pharmaceuticals

Financials

Sales 2024 * 60.06B 65.64B 60.66B 89.97B Sales 2025 * 63.61B 69.52B 64.24B 95.29B Capitalization 187B 205B 189B 281B
Net income 2024 * 13.41B 14.66B 13.54B 20.09B Net income 2025 * 14.87B 16.25B 15.02B 22.27B EV / Sales 2024 * 3.35 x
Net Debt 2024 * 13.78B 15.06B 13.91B 20.64B Net Debt 2025 * 7.77B 8.49B 7.85B 11.64B EV / Sales 2025 * 3.07 x
P/E ratio 2024 *
13.5 x
P/E ratio 2025 *
12.3 x
Employees 103,605
Yield 2024 *
4.19%
Yield 2025 *
4.34%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 66 95-12-31
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company